AstraZeneca struck a sweeping collaboration with China’s CSPC Pharmaceutical Group to add next‑generation weight‑loss candidates to its metabolic pipeline. The deal includes an upfront payment of $1.2 billion and rights to multiple one‑month injectable GLP‑1/GIP receptor agonists and long‑acting delivery technology. CSPC retains regional rights in Greater China while AstraZeneca gains global development and commercialization control. The agreement names SYH2082, a clinical‑ready long‑acting peptide hitting GLP‑1/GIP targets, among the lead assets. AstraZeneca will assume late‑stage development and global commercialization after early trials; CSPC will progress several candidates through Phase I. The pact includes up to $3.5 billion in R&D milestones and multibillion-dollar sales milestones, reflecting broad option economics across eight programs. Companies cited the deal as strategically complementary to AstraZeneca’s existing weight‑management and metabolic portfolio and its $15 billion China investment plan. For drug developers, the transaction underscores rapid consolidation in obesity therapeutics and the value of long‑acting peptide platforms for differentiated dosing schedules.